Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?
- DOI
- 10.4149/neo_2026_260404n105
- Published
- 2026 Aug
- Container
- Neoplasma
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.4149/neo_2026_260404n105,
title = {Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?},
author = {Lukáš J and Gálffy B and Fliegová S and Sninská Z and Harvanová Ľ and Slezáková K and Sopko L},
year = {2026},
journal = {Neoplasma},
doi = {10.4149/neo_2026_260404n105},
url = {https://doi.org/10.4149/neo_2026_260404n105}
}RIS
TY - JOUR TI - Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration? AU - Lukáš J AU - Gálffy B AU - Fliegová S AU - Sninská Z AU - Harvanová Ľ AU - Slezáková K AU - Sopko L PY - 2026 JO - Neoplasma DO - 10.4149/neo_2026_260404n105 UR - https://doi.org/10.4149/neo_2026_260404n105 ER -
APA
J, L., B, G., S, F., Z, S., Ľ, H., K, S., & L, S. (2026). Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?. Neoplasma. https://doi.org/10.4149/neo_2026_260404n105
Source records
- pubmed · retrieved 2026-09-26T06:52:36.551Z